TROAP Antibody

What is TROAP and why is it significant in biomedical research?

TROAP (Trophinin Associated Protein), also known as Tastin, is a cytoplasmic protein comprising 778 amino acid residues with potential phosphorylation sites for protein kinases. It plays significant roles in embryo transplantation, microtubule regulation, and centrosome integrity . TROAP has emerged as an important research target due to its involvement in various pathological conditions, particularly in cancer progression. The protein is highly expressed in bone marrow, testis, and thymus under normal physiological conditions . Its significance in research has grown substantially as studies have demonstrated its upregulation in multiple cancer types, making TROAP antibodies valuable tools for investigating cancer pathogenesis and potential therapeutic approaches.

What are the key characteristics of commercially available TROAP antibodies?

TROAP antibodies are available in both monoclonal and polyclonal formats, targeting different epitopes of the protein. Key characteristics include:

How does TROAP function at the molecular level?

TROAP functions as a cytoplasmic protein involved in multiple cellular processes. At the molecular level, research has shown that TROAP directly interacts with dual specificity tyrosine phosphorylation regulated kinase 1A/B (DYRK1A/B), resulting in cytoplasmic retention of these proteins . This interaction promotes cell cycle progression through activation of the Akt/GSK-3β signaling pathway . The protein contains potential phosphorylation sites for protein kinases, suggesting its role in signal transduction. In normal cells, TROAP is involved in centrosome integrity maintenance, while in pathological conditions such as cancer, its overexpression contributes to enhanced cell proliferation and malignant transformation by altering key signaling pathways.

What are the recommended protocols for TROAP antibody application in immunohistochemistry?

For effective immunohistochemistry (IHC) using TROAP antibodies, the following optimized protocol has been validated in research studies:

• Sample Preparation:

  • Cut paraffin-embedded tissue samples into 4-5 μm sections

  • Deparaffinize sections and boil in 0.1 M citrate buffer (pH 6.0) for 20 minutes for antigen retrieval

  • Inactivate endogenous peroxidases with 3% hydrogen peroxide for 10 minutes

• Antibody Incubation:

  • Apply primary TROAP antibody (recommended dilution 1:100) and incubate at 4°C overnight

  • Wash sections with phosphate-buffered saline

  • Incubate with biotinylated secondary antibody for 30 minutes at room temperature

  • Apply 3,3'-diaminobenzidine for 5 minutes

• Counterstaining and Mounting:

  • Counterstain slides with light hematoxylin

  • Dehydrate and apply coverslips

• Evaluation and Scoring:

  • Score staining intensity on a scale of 0-3 (0=absent, 1=weak, 2=moderate, 3=strong)

  • Determine percentage of positive tumor cells (0-100%)

  • Calculate weighted score by multiplying intensity score by percentage of positive cells

  • Scores typically range from 0 to 3, with scores ≤0.80 considered "low expression" and >0.80 as "high expression"

This protocol has demonstrated reproducible results in clinical research evaluating TROAP expression in various tumor tissues .

How should researchers optimize Western blotting conditions for TROAP detection?

For optimal Western blotting results with TROAP antibodies, researchers should follow these recommended procedures:

• Sample Preparation:

  • Harvest cells and lyse them in RIPA buffer supplemented with protease inhibitors

  • Separate proteins using SDS-PAGE and transfer onto PVDF membranes

• Blocking and Antibody Incubation:

  • Block membranes with 5% non-fat milk

  • Incubate with primary anti-TROAP antibody (recommended dilution range: 1/200 - 1/1000)

  • Use β-ACTIN as a normalization control (recommended dilution: 1:5000)

• Washing and Detection:

  • Wash membranes three times in PBST, each wash lasting 10 minutes

  • Incubate with appropriate secondary antibody

  • Visualize bands using standard chemiluminescence detection systems

• Expected Results:

  • Observe predicted molecular weight of approximately 110 kDa for TROAP protein

  • Quantify band intensities using image analysis software such as ImageJ

Optimizing antibody concentration is crucial for detecting TROAP effectively while minimizing background noise. Researchers should validate specificity by including positive and negative controls, and consider using recombinant TROAP protein as a reference standard when available .

What approaches can be used for validating TROAP antibody specificity?

Validating antibody specificity is critical for ensuring reliable experimental results. For TROAP antibodies, several complementary validation approaches are recommended:

• Western Blot Analysis:

  • Perform Western blot on a panel of human tissues and cell lines

  • Verify detection of bands at the predicted molecular weight (approximately 110 kDa)

  • For questionable results, conduct revalidation using TROAP overexpression lysates

• Protein Array Analysis:

  • Utilize protein arrays containing 384 different antigens including TROAP

  • Analyze antibody binding profile to assess cross-reactivity

• Enhanced Validation Methods:

  • Genetic Validation: Compare antibody staining in TROAP-expressing vs. TROAP-knockout cells

  • Recombinant Expression Validation: Test antibody on cells with controlled TROAP expression

  • Independent Antibody Validation: Compare staining patterns with multiple antibodies targeting different TROAP epitopes

  • Orthogonal Validation: Correlate protein detection with mRNA expression data

  • Capture MS Validation: Verify antibody-captured proteins by mass spectrometry

• Immunohistochemistry Validation:

  • Assess staining patterns across 44 normal tissues

  • Evaluate consistency between immunohistochemistry data and consensus RNA levels

  • Classify validation results as Enhanced, Supported, Approved, or Uncertain based on staining pattern consistency

These validation approaches help ensure that experimental findings accurately reflect TROAP biology rather than artifacts of non-specific antibody binding.

How is TROAP expression correlated with cancer progression and prognosis?

Multiple studies have demonstrated significant correlations between TROAP expression and cancer outcomes across various malignancies:

These consistent findings across multiple cancer types establish TROAP as a promising biomarker for cancer progression and therapeutic response prediction.

What molecular mechanisms underlie TROAP's role in cancer progression?

Research has uncovered several key molecular mechanisms through which TROAP contributes to cancer progression:

• DYRK1A/B Regulation:

  • TROAP directly binds to dual specificity tyrosine phosphorylation regulated kinase 1A/B (DYRK1A/B)

  • This interaction causes cytoplasmic retention of DYRK1A/B proteins

  • Leads to promotion of cell cycle progression via activation of Akt/GSK-3β signaling pathway

• Cell Cycle Regulation:

  • Patients with high TROAP expression show enrichment in cell cycle-related pathways

  • TROAP overexpression is associated with enhanced DNA replication and cell proliferation

  • Silencing TROAP with shRNA attenuates malignant proliferation of cancer cells both in vitro and in vivo

• Immune Microenvironment Modulation:

  • TROAP expression negatively correlates with immune infiltration in tumors

  • High TROAP expression is associated with reduced stromal and immune scores

  • TROAP levels show correlations with immune checkpoint molecules:

    • Positive correlation with PVR, CD276, and CD47

    • Negative correlation with HLA-E and CD19

• microRNA Regulation:

  • In HCC, TROAP is significantly upregulated by miR-142-5p

  • This regulatory relationship contributes to poor survival outcomes in HCC patients

Understanding these mechanisms provides potential therapeutic opportunities, as demonstrated by the finding that combination of cisplatin with DYRK1 inhibitor AZ191 effectively inhibits tumor growth in mouse models with high TROAP expression .

How can TROAP antibodies be used in identifying potential therapeutic targets in cancer?

TROAP antibodies serve as valuable tools for identifying and validating potential therapeutic targets in cancer research through several approaches:

• Protein-Protein Interaction Studies:

  • TROAP antibodies can be employed in co-immunoprecipitation experiments to identify novel TROAP-interacting proteins

  • This approach has revealed crucial interactions such as TROAP binding to DYRK1A/B, which represents a potential therapeutic target

  • Inhibiting DYRK1 with AZ191 shows synergistic effects with cisplatin in TROAP-overexpressing tumors

• Stratification for Immunotherapy Response:

  • Immunohistochemistry with TROAP antibodies can help stratify patients for immunotherapy response prediction

  • Research has shown that TROAP expression levels correlate with differential responses to nivolumab and everolimus in renal cell carcinoma

  • Lower TROAP expression has been associated with better response to anti-PD-1 immunotherapy across multiple cancer types

• Validation of TROAP-Targeting Therapeutics:

  • TROAP antibodies are essential for monitoring protein knockdown efficiency in therapeutic development

  • They enable verification of target engagement in studies using TROAP-targeting approaches such as siRNA, shRNA, or novel degradation technologies

  • The PROTABs (proteolysis-targeting antibodies) technology represents a potential approach for TROAP degradation by tethering cell-surface E3 ubiquitin ligases to transmembrane proteins

• Biomarker Development:

  • TROAP antibody-based assays can be developed for:

    • Patient stratification in clinical trials

    • Monitoring treatment response

    • Identifying patients likely to benefit from specific therapeutic approaches

  • Multi-parameter analyses combining TROAP with other markers can enhance predictive accuracy for treatment response

How can researchers effectively design experiments to investigate TROAP's role in tumor microenvironment modulation?

To effectively investigate TROAP's impact on the tumor microenvironment, researchers should consider a comprehensive experimental design approach:

• Single-Cell Analysis:

  • Apply single-cell RNA sequencing to simultaneously evaluate TROAP expression and immune cell populations

  • Utilize single-sample gene set enrichment analysis (ssGSEA) to assess correlation between TROAP expression and immune cell infiltration patterns

  • This approach has revealed that low TROAP expression correlates with higher infiltration of CD4 T cells, dendritic cells, and macrophages

• Spatial Transcriptomics and Multiplex Immunofluorescence:

  • Combine TROAP antibody staining with immune cell markers to visualize spatial relationships

  • Map TROAP expression patterns in relation to tumor-infiltrating immune cells

  • Correlate spatial distribution with clinical outcomes and treatment responses

• In vivo Models with Immune Monitoring:

  • Develop TROAP-modulated cancer cell lines (overexpression/knockdown)

  • Implant these cells in immunocompetent mouse models

  • Monitor changes in:

    • Tumor growth kinetics

    • Immune cell infiltration profiles

    • Response to immunotherapy

    • Expression of immune checkpoint molecules like PVR, CD276, CD47, HLA-E, and CD19

• Mechanistic Studies:

  • Perform chromatin immunoprecipitation (ChIP) to identify transcription factors regulating TROAP

  • Use RNA-seq and pathway analysis to identify molecular networks affected by TROAP modulation

  • Conduct co-immunoprecipitation with TROAP antibodies followed by mass spectrometry to identify novel interaction partners in immune cells

• Validation in Clinical Samples:

  • Create tissue microarrays from patient samples with varied TROAP expression

  • Perform multiplex staining for TROAP, immune cell markers, and functional markers

  • Correlate TROAP expression with Th2 cell infiltration and other immune parameters

This multifaceted approach allows researchers to comprehensively characterize how TROAP influences the tumor immune microenvironment across different cancer types.

What approaches should be used to address contradictory findings in TROAP research across different cancer types?

When addressing contradictory findings in TROAP research across different cancer types, researchers should implement a systematic approach:

• Meta-Analysis of Existing Data:

  • Perform comprehensive meta-analysis across multiple cancer datasets (TCGA, GEO, etc.)

  • Stratify analysis by cancer type, stage, and molecular subtypes

  • Standardize effect size measurements to enable direct comparisons

  • This approach has revealed that while TROAP is upregulated in most tumor types, its prognostic significance varies between cancer types

• Consideration of Tissue-Specific Contexts:

  • Investigate tissue-specific interactomes using TROAP antibodies for co-immunoprecipitation

  • Analyze tissue-specific signaling pathways that may modulate TROAP function

  • Compare TROAP expression patterns in matched primary tumors and metastases to understand context-dependent roles

• Isoform-Specific Analysis:

  • Design experiments to distinguish between potential TROAP isoforms or post-translational modifications

  • Utilize antibodies targeting different epitopes to evaluate isoform-specific expression patterns

  • Investigate whether contradictory findings may stem from detection of different TROAP variants

• Multi-Omics Integration:

  • Combine proteomics, transcriptomics, and genomics data to assess TROAP in a systems biology context

  • Identify cancer-specific regulatory networks that may explain differential TROAP functions

  • Correlate TROAP expression with mutation profiles, copy number alterations, and methylation patterns

• Functional Validation in Multiple Models:

  • Perform parallel TROAP manipulation (overexpression/knockdown) in cell lines from different cancer types

  • Assess phenotypic consequences in standardized assays (proliferation, invasion, therapy response)

  • Validate findings in patient-derived organoids and xenograft models from various cancer types

This systematic approach can help reconcile seemingly contradictory findings by identifying context-dependent regulatory mechanisms and functions of TROAP across different cancer types.

How can researchers optimize TROAP antibody-based techniques for detecting low abundance TROAP in normal tissues?

Detecting low abundance TROAP in normal tissues presents a technical challenge that requires optimization of antibody-based techniques:

• Signal Amplification Strategies:

  • Implement tyramide signal amplification (TSA) for immunohistochemistry and immunofluorescence

  • Use polymer-based detection systems that provide higher sensitivity than conventional avidin-biotin methods

  • Consider proximity ligation assay (PLA) for detecting low levels of protein-protein interactions involving TROAP

• Sample Preparation Optimization:

  • Evaluate different fixation protocols to preserve TROAP epitopes

  • Compare antigen retrieval methods (citrate buffer pH 6.0 has shown good results for TROAP)

  • Consider membrane permeabilization optimization for intracellular TROAP detection

• Antibody Selection and Validation:

  • Screen multiple TROAP antibodies targeting different epitopes (AA 1-778, AA 6-33, AA 181-280)

  • Validate antibody sensitivity using titrations of recombinant TROAP protein

  • Consider using antibody cocktails targeting multiple epitopes to enhance detection sensitivity

• Enrichment Techniques:

  • Implement immunoprecipitation prior to Western blotting to concentrate TROAP protein

  • Consider laser capture microdissection to isolate specific cell populations with expected TROAP expression

  • Use highly sensitive detection methods such as ECL Prime or SuperSignal West Femto for Western blotting

• Quantitative Assessment:

  • Employ digital image analysis with appropriate software for quantifying weak signals

  • Use appropriate positive controls with known TROAP expression levels

  • Calculate the limit of detection for each antibody under optimized conditions

  • Implement standards to ensure reproducibility across experiments

• Alternative Detection Methods:

  • Consider mass spectrometry-based approaches for TROAP detection in normal tissues

  • Employ RNA in situ hybridization as a complementary method to confirm protein findings

  • Use reverse phase protein arrays (RPPA) for high-throughput, sensitive detection

These optimizations can significantly improve the detection of low abundance TROAP in normal tissues, enabling more accurate characterization of its physiological functions.

What are the most common technical challenges when using TROAP antibodies, and how can they be overcome?

Researchers frequently encounter several technical challenges when working with TROAP antibodies. Here are the most common issues and strategies to address them:

• Non-specific Binding:

  • Challenge: Background staining in Western blots or immunohistochemistry

  • Solutions:

    • Increase blocking duration and concentration (5% BSA or non-fat milk)

    • Optimize antibody dilutions (typically 1:100 for IHC, 1:200-1:1000 for WB)

    • Include additional washing steps with increased stringency

    • Pre-absorb antibody with non-specific proteins

• Inconsistent Detection:

  • Challenge: Variable staining intensity across experiments

  • Solutions:

    • Standardize sample preparation protocols

    • Use automated staining platforms when available

    • Include positive and negative controls in each experiment

    • Prepare larger batches of working antibody dilutions to minimize preparation variability

• Epitope Masking:

  • Challenge: Fixation-induced masking of TROAP epitopes

  • Solutions:

    • Optimize antigen retrieval methods (0.1M citrate buffer pH 6.0 for 20 minutes has shown good results)

    • Compare heat-induced vs. enzymatic epitope retrieval

    • Evaluate alternative fixation protocols

    • Select antibodies targeting epitopes less affected by fixation

• Cross-reactivity:

  • Challenge: Antibody binding to proteins other than TROAP

  • Solutions:

    • Validate specificity using TROAP knockdown/knockout controls

    • Compare results with multiple antibodies targeting different TROAP epitopes

    • Perform peptide competition assays

    • Use Western blotting to confirm single band detection at the expected molecular weight (110 kDa)

• Low Signal in Normal Tissues:

  • Challenge: Difficulty detecting physiological TROAP levels

  • Solutions:

    • Implement signal amplification methods (TSA, high-sensitivity ECL)

    • Increase primary antibody incubation time (overnight at 4°C)

    • Optimize tissue sectioning thickness (4-5 μm recommended)

    • Consider alternative detection systems with higher sensitivity

By implementing these strategies, researchers can significantly improve the reliability and reproducibility of experimental results using TROAP antibodies.

How should researchers interpret apparent discrepancies between TROAP protein and mRNA expression data?

Discrepancies between TROAP protein and mRNA expression data are common and require careful interpretation:

• Post-transcriptional Regulation:

  • TROAP may be subject to microRNA regulation, as demonstrated by the influence of miR-142-5p on TROAP levels in HCC

  • Assess potential microRNA binding sites in TROAP mRNA

  • Investigate RNA-binding proteins that might affect TROAP mRNA stability or translation

• Post-translational Modifications and Protein Stability:

  • Examine potential post-translational modifications affecting TROAP stability

  • Investigate ubiquitination pathways that might regulate TROAP protein turnover

  • Consider measuring TROAP protein half-life under different conditions

  • Assess proteasomal and lysosomal degradation pathways

• Technical Considerations:

  • Evaluate antibody specificity for detecting specific TROAP isoforms or modified forms

  • Compare results from multiple antibodies targeting different TROAP epitopes

  • Assess consistency between immunohistochemistry data and consensus RNA levels, which can be categorized as high, medium, low, or very low consistency

  • Consider sensitivity limitations of protein detection methods versus mRNA quantification

• Biological Variation:

  • Account for cell type-specific translation efficiency differences

  • Consider spatial heterogeneity within tumor samples

  • Evaluate temporal dynamics of TROAP expression

  • Assess whether discrepancies correlate with specific clinical or pathological features

• Integrative Analysis Approach:

  • Combine protein and mRNA data with additional -omics layers

  • Perform correlation analysis between TROAP protein and mRNA across multiple samples

  • Use visualization tools to identify patterns in discrepancies

  • Consider single-cell analysis to resolve cell type-specific differences

Understanding the nature of these discrepancies can provide insights into TROAP regulation and function that may not be apparent from either dataset alone.

What quality control measures should be implemented when using TROAP antibodies in multi-center clinical studies?

For multi-center clinical studies utilizing TROAP antibodies, implementing robust quality control measures is essential to ensure data consistency and reliability:

• Antibody Standardization:

  • Use antibodies from the same manufacturer, lot, and clone across all sites

  • Conduct centralized validation of each antibody lot before distribution to study sites

  • Provide detailed specifications for storage and handling (temperature, aliquoting recommendations)

  • Consider using recombinant antibodies when available for improved consistency

• Protocol Harmonization:

  • Develop detailed standard operating procedures (SOPs) for all antibody-based techniques

  • Specify exact reagents, equipment, and conditions for each assay

  • Conduct initial training workshops for technicians from all participating centers

  • Provide video protocols to demonstrate critical steps

• Reference Standards:

  • Distribute reference samples with known TROAP expression levels to all sites

  • Include tissue microarrays containing gradient controls for immunohistochemistry

  • Establish calibration curves for quantitative assays using recombinant TROAP standards

  • Provide standardized positive and negative control samples

• Centralized Analysis:

  • Consider centralized staining for immunohistochemistry when feasible

  • Implement digital pathology for centralized scoring of immunohistochemistry

  • Establish an expert panel for resolving discrepant or difficult-to-interpret cases

  • Use automated image analysis software with standardized algorithms for quantification

• Inter-laboratory Validation:

  • Conduct regular ring trials where identical samples are analyzed across all sites

  • Calculate inter-laboratory coefficient of variation for quantitative measurements

  • Address systematic biases through calibration factors if necessary

  • Document and report site-specific performance metrics

• Data Quality Monitoring:

  • Implement real-time quality monitoring throughout the study

  • Establish acceptance criteria for assay performance

  • Develop procedures for handling and documenting protocol deviations

  • Create a central database for tracking quality control metrics

These comprehensive quality control measures ensure that TROAP antibody-based data generated across multiple sites maintains high reliability and reproducibility, critical for clinical research and biomarker development.

What emerging technologies might enhance the utility of TROAP antibodies in research?

Several emerging technologies show promise for enhancing TROAP antibody applications in research:

• Proteolysis-Targeting Antibodies (PROTABs):

  • This novel technology tethers cell-surface E3 ubiquitin ligases to transmembrane proteins

  • Could potentially be adapted for targeted TROAP degradation in specific tissues

  • Offers advantages of potent, bioavailable, and tissue-selective degradation of target proteins

• Spatial Proteomics:

  • Combining TROAP antibodies with multiplexed imaging technologies like CODEX, Imaging Mass Cytometry, or GeoMx DSP

  • Enables simultaneous visualization of TROAP and dozens of other proteins with spatial context

  • Facilitates understanding of TROAP's role in the complex tumor microenvironment

• Nanobody and Single-Domain Antibody Technology:

  • Development of TROAP-specific nanobodies for improved tissue penetration

  • Single-domain antibodies offer advantages in size, stability, and production

  • Potential for intracellular delivery to target TROAP in living cells

• BiTE and CAR-T Cell Approaches:

  • Design of bispecific T-cell engagers (BiTEs) incorporating TROAP-binding domains

  • Development of CAR-T cells targeting TROAP-overexpressing cancer cells

  • Potential for targeted immunotherapy approaches in TROAP-high tumors

• Microfluidic Antibody Analysis:

  • High-throughput microfluidic platforms for single-cell analysis of TROAP expression

  • Enables correlation of TROAP levels with multiple cellular parameters at single-cell resolution

  • Potential for identifying rare subpopulations with distinct TROAP expression patterns

• Digital Pathology and AI Integration:

  • Machine learning algorithms for automated quantification of TROAP staining patterns

  • AI-based image analysis for correlating TROAP expression with histopathological features

  • Deep learning approaches for predicting treatment response based on TROAP expression patterns

These technologies represent promising directions for enhancing the utility of TROAP antibodies in both basic research and clinical applications.

How might TROAP antibodies contribute to the development of precision medicine approaches?

TROAP antibodies have significant potential to advance precision medicine approaches through several applications:

• Biomarker-Guided Treatment Selection:

  • TROAP antibody-based assays can identify patients likely to benefit from specific therapies

  • Research has shown that TROAP expression correlates with response to treatments including:

    • Nivolumab immunotherapy in renal cell carcinoma

    • Everolimus targeted therapy

    • DYRK1 inhibitors in combination with cisplatin

  • Implementation of standardized TROAP IHC scoring systems could facilitate treatment stratification

• Monitoring Treatment Response and Resistance:

  • Serial measurements of TROAP expression during treatment

  • Changes in TROAP levels may indicate developing resistance mechanisms

  • Potential for liquid biopsy applications detecting TROAP in circulating tumor cells

• Companion Diagnostics Development:

  • TROAP antibody-based assays as companion diagnostics for emerging therapeutics

  • Integration with other biomarkers for enhanced predictive accuracy

  • Standardized immunohistochemistry protocols suitable for clinical implementation

• Novel Therapeutic Target Identification:

  • TROAP antibodies in proteomic analyses to identify:

    • Cancer-specific TROAP interaction networks

    • Downstream effectors of TROAP signaling

    • Potential vulnerabilities in TROAP-overexpressing tumors

  • These insights can guide development of targeted therapeutics

• Patient Stratification for Clinical Trials:

  • TROAP expression assessment for patient enrollment in targeted therapy trials

  • Particularly relevant for trials of agents targeting:

    • DYRK1A/B pathway inhibitors

    • Akt/GSK-3β pathway modulators

    • Cell cycle regulators

  • Stratification based on TROAP expression may increase statistical power and identify responsive subgroups

• Development of TROAP-Targeted Therapies:

  • TROAP antibodies as targeting moieties for:

    • Antibody-drug conjugates

    • Nanoparticle delivery systems

    • Radioimmunotherapy approaches

  • Leveraging TROAP overexpression in tumors for selective targeting

The implementation of TROAP antibodies in these precision medicine approaches could significantly improve patient outcomes by enabling more targeted and effective therapeutic strategies based on individual tumor characteristics.

What are the most promising research directions for understanding TROAP's role in normal physiological processes?

While much research has focused on TROAP's role in cancer, several promising research directions could enhance our understanding of its normal physiological functions:

• Developmental Biology:

  • TROAP was initially identified for its role in embryo transplantation

  • Further investigation of TROAP in:

    • Early embryonic development

    • Implantation biology

    • Trophoblast function and placentation

  • Conditional knockout models to elucidate stage-specific roles

• Stem Cell Biology:

  • Investigation of TROAP in stem cell maintenance and differentiation

  • Analysis of TROAP expression in:

    • Embryonic stem cells

    • Induced pluripotent stem cells

    • Adult tissue-specific stem cells

  • Potential role in cellular reprogramming and differentiation pathways

• Cell Division and Cytoskeletal Regulation:

  • TROAP's involvement in centrosome integrity and microtubule regulation

  • Investigation of:

    • Mitotic spindle formation and function

    • Chromosomal segregation processes

    • Cytokinesis mechanisms

  • Identification of TROAP's interactome during different cell cycle phases

• Tissue-Specific Functions:

  • Detailed analysis of TROAP in tissues with physiological expression:

    • Bone marrow hematopoiesis

    • Testicular function and spermatogenesis

    • Thymic development and function

  • Development of tissue-specific conditional knockout models

• Immune System Regulation:

  • Investigation of TROAP's potential roles in:

    • T-cell development and function

    • Antigen presentation processes

    • Immune cell migration and cytoskeletal remodeling

  • Correlation with specific immune cell subsets and functions

• Signaling Pathway Integration:

  • Comprehensive mapping of TROAP in normal signaling networks:

    • DYRK1A/B pathway interactions in non-cancerous contexts

    • Akt/GSK-3β signaling in normal cellular homeostasis

    • Integration with other developmental and homeostatic pathways